Refrigerators
The biopharmaceutical industry has argued that the five yearws of protection offeredby Rep. Henryh Waxman, D-Los Angeles, in H.R. 1427 would stifle But the in a repor t earlier this month said the 12 to 14 years that the industry has said publicly that it wante also would hurt innovation and delay access tocheaper drugs. Rep. Anna Eshoo’xs H.R. 1548 calls for a 12-year period of data basically protecting the patents covering innovativebiotech therapies.
In a letter to Waxman, Nancy-Ann DeParle, Obama’as health-care reform director, and budget director Pete Orszagsaid “the seven-year policy in the FY 2010 Budgef is a generous compromise between what the FTC researc h has concluded and what the pharmaceutical industrgy has advocated.” , however, said it is “extremelhy concerned” that the seven-year plan is “a risky shortcut to “We believe this abbreviatedx period will undermine the incentives necessary for continued biotech researcu into breakthrough medicines and cures for diseases such as multiple sclerosis, Alzheimer’s and HIV/AIDS as well as unme medical needs,” BIO President and CEO Jim Greenwoo d said in a statement.
Besides patent exclusivity, the industry has argue that drugs developed by biotec hcompanies can’t be copied like pharmaceutical drugs because they are compled to make and the finished products can differ.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment